The information in this website is intended only for healthcare professionals. By entering this site, you are confirming that you are a healthcare professional.
The information in this website is intended only for laboratory professionals. By entering this site, you are confirming that you are a laboratory professional.
Lower requirements mean more patients can get actionable results.
Complete biomarker results should be available in days, not weeks.
Testing should be reimbursed to help reduce patient expenses.
Next-generation sequencing (NGS) testing enables delivery of multiple biomarker results from one sample, minimizing the risk of depleting tissues and additional biopsies.
There are currently five biomarkers associated with approved therapies for NSCLC, with many others in clinical trials. In fact, 73%1 of all drugs in the oncology pipeline have associated biomarkers.
Today, NGS panel testing is the recommended approach to quickly assess patients because single-gene testing requires more tissue and time.2 The need for NGS will increase as new biomarkers are discovered. But not all NGS tests are equal.
Using NGS tests with larger tissue requirements may restrict many patients from receiving the full range of actionable biomarker results.
Insufficient sample can lead to test rejection or failure and therefore rebiopsies and treatment delays.
A comparison of two NSCLC FDA-approved companion diagnostic (CDx) tests reveals a significant difference in tissue requirements.
Outsourcing was a logical choice in the early days of biomarker testing.
The science was relatively new, it wasn’t reimbursable, and there were too few biomarkers to justify in-house testing. These former challenges are now becoming irrelevant.
Today, the science has matured, the technology is easy to implement, and more hospitals are now bringing NGS testing in-house to benefit patients.
NGS biomarker testing is more accessible to hospitals because it's now:
Simple: NGS technology is now easy for hospitals to implement in-house
Significant: 73%1 of drugs in the oncology pipeline are associated with molecular biomarkers
Reimbursable: coverage is available nationally by Medicare, and locally by many of the country’s largest commercial payers
To expedite treatment selection for NSCLC patients and help ensure those patients receive the best outcomes, the OncomineTM Dx Target Test is the solution.
External labs, such as Foundation Medicine, offer a single panel with biomarkers for every type of cancer. Why test for hundreds of genes that aren’t actionable for your patient?
In 46% to 80%3 of patient cases, the samples are simply too small for these large panels.4 This testing approach may require invasive re-biopsies or lead to suboptimal therapy.
The Oncomine Dx Target Test is able to return a full biomarker report for NSCLC from much smaller tumor samples, benefitting more patients.
Outsourced testing can cost more due to third-party margins, leading to higher healthcare costs overall, regardless of payer.
In-house testing can help reduce cost to the healthcare system and patients with the right NGS test. The Oncomine Dx Target Test is reimbursed nationally by Medicare and the top 20 commercial payers, enabling access to affordable NSCLC testing for more than 180 million people in the U.S.
Results from third-party labs can take weeks5—time that late-stage NSCLC patients don’t have to spare.
In-house testing with the Oncomine Dx Target Test is completed in as little as four days6, and returns a comprehensive report on relevant NSCLC biomarkers.
The ability to expedite the testing process enables faster start of the right treatment for your patients.
The location, speed, and diagnostic testing method all affect patient outcomes. This is why hospitals are bringing biomarker testing in-house to offer the best possible care and to position themselves as the local treatment center of choice.
In-house testing with the Oncomine Dx Target Test, the first FDA-approved in vitro diagnostic for NSCLC, is an NGS-based solution that simultaneously delivers multiple actionable biomarker results from one small sample in as little as four days.
Are you ready to bring biomarker testing in-house? Download this simple discussion guide to start the conversation with your care team.
While in-house testing can help expedite targeted therapy selection to achieve better outcomes for your NSCLC patients, they can still benefit from lower tissue requirements if you order Onocmine Dx Target Tests through the following commercial labs:
|Reference lab||Telephone number||Website|
|Cancer Genetics, Inc.||1-888-700-7110||www.cancergenetics.com|
(a division of LabCorp)
|Quest Laboratories, Inc.||1-972-966-7050||www.medfusionservices.com|
|NeoGenomics Laboratories, Inc.||1-866-776-5907||www.neogenomics.com|
Multi-biomarker testing for more effective patient care is here today. If you or members of your care team have questions, our team is available to answer them.
The Oncomine Platform software tools have moved. Customers looking for Oncomine Research Premium Edition should update their bookmarks to software.oncomine.com.
The Oncomine Dx Target Test is For in Vitro Diagnostic Use.